

## 1 Genetic Associations of Lipid-Lowering Drugs and Parkinson's Disease: A Mendelian 2 Randomization Study

3  
4 Lin Shen MSc<sup>\*1</sup>, Yifan Yang MSc<sup>\*2</sup>, Yi Li PhD<sup>1</sup>, Hok Leong Chin<sup>3</sup>, Helen Huang<sup>4</sup>, Bernard Man Yung  
5 Cheung MB BChir PhD FRCP<sup>5</sup>, Gary Tse MD PhD FRCP FRCPath<sup>6,7</sup>, Oscar Hou In Chou MSc<sup>3#</sup>,  
6 Jiandong Zhou PhD<sup>8,9#</sup>  
7

8 <sup>1</sup> Department of Gastroenterology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an,  
9 Shaanxi Province, China

10 <sup>2</sup> School of Management, Xi'an Jiaotong University, Xi'an, China

11 <sup>3</sup> Division of Neurology, Department of Pediatrics, University of Chicago, Chicago, IL, USA

12 <sup>3</sup> Division of Clinical Pharmacology and Therapeutics, Department of Medicine, University of Hong  
13 Kong, Hong Kong, China

14 <sup>4</sup> Diabetes Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong  
15 Kong, China

16 <sup>5</sup> School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong,  
17 China

18 <sup>6</sup> Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of  
19 Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin  
20 300211, China

21 <sup>7</sup> Kent and Medway Medical School, Canterbury, United Kingdom

22 <sup>8</sup> Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University  
23 of Hong Kong, Hong Kong, China

24 <sup>9</sup> Division of Health Science, Warwick Medical School, University of Warwick, United Kingdom

25  
26 \* Co-first authors

27 # Correspondence to:

28 Oscar Hou In Chou, MSc,

29 Division of Clinical Pharmacology and Therapeutics, Department of Medicine, School of Clinical  
30 Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China

31 Diabetes Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong,  
32 China

33 Email: [gary.tse@kmms.ac.uk](mailto:gary.tse@kmms.ac.uk)

34  
35 Jiandong Zhou, Ph.D.

36 Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of  
37 Hong Kong, Hong Kong, China

38 Division of Health Science, Warwick Medical School, University of Warwick, United Kingdom

39 Email: [Jiandong.Zhou@warwick.ac.uk](mailto:Jiandong.Zhou@warwick.ac.uk)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

40 **Abstract**

41 **Background:** There is a need to establish the role of lipid-lowering agents as a therapeutic option for  
42 Parkinson's Disease (PD), but its associations remain elusive. This study investigated genetic variants  
43 proxying lipid-lowering agents through HMGCR, NPC1L1, and PCSK9 inhibitors to determine casual  
44 associations with PD risk.

45 **Methods:** We utilized a two-sample Mendelian randomization (MR) framework, where low-density  
46 lipoprotein (LDL) was the outcome of interest. Genetic associations with LDL were extracted from the  
47 Global Lipids Genetics Consortium. Summary statistics for PD were extracted from two GWAS  
48 datasets, consistent of 1,843 PD cases and 216,630 control in the first dataset and 1,570 PD cases and  
49 1,259 controls in the second dataset. Instrumental variables (IV) were optimized with positive control  
50 analyses on cardiovascular and metabolic outcomes. IV-exposure associations from LDL GWAS data  
51 were integrated with IV-outcome associations from the PD GWAS data. The inverse variance weighted  
52 method was applied. Bayesian colocalization analysis identified target gene regions for LDL and PD.

53 **Results:** Genetic variations in *HMGCR* were significantly associated with a reduced risk of PD (odds  
54 ratio [OR] = 0.54, 95% CI 0.34-0.86). However, variation in *HMGCR* was associated with an increased  
55 risk of the tremor-dominant (TD) subtype compared to the postural instability/gait difficulty (PIGD)  
56 subtype (OR = 8.43, 95% CI 2.12-33.52). There were trends with increased risk for the TD subtype in  
57 *NPC1L1* and a decreased risk in *PCSK9* but these findings did not meet the Bonferroni threshold. We  
58 identified two single nucleotide polymorphisms (SNPs) in *HMGCR* within the same genomic region of  
59 close proximity, with rs12916 as the leading SNP associated with LDL and rs10942735 as the leading  
60 SNP associated with PD.

61 **Conclusion:** A casual association between *HMGCR* inhibition and reduced overall PD risk was

62 identified, but there were increased the risks of tremor-dominant subtypes.

63

64 **Keywords:** Low-density lipoprotein, Parkinson's disease, lipid-lowering drug, mendelian

65 randomization, single nucleotide polymorphisms

## 66 Introduction

67 Parkinson disease (PD) is the second most common neurodegenerative disease with progressive  
68 nature<sup>1</sup>. In 2017, there were 1.02 million incident cases of PD as reported by the Global Burden of  
69 Disease<sup>2</sup>. The determinants of PD are multifactorial, with age-related susceptibilities being the biggest  
70 risk factor for PD with a median onset of 60 years of age<sup>3</sup>. Various studies have identified that genetic  
71 susceptibility could modify the effects of environmental stressors. In a recent meta-analysis of  
72 genome-wide association studies, 70 variants involved with the folding of alpha-synuclein may  
73 contribute to PD risk suggesting a genetic etiology<sup>4-6</sup>. Unfortunately, there are a lack of therapies that  
74 could delay the progression of disease.

75 With recent advancements in surrounding lipid-lowering therapies, targets of cholesterol metabolism  
76 may be of interest in PD. Lipids are becoming increasingly recognized to play a significant role in PD.  
77 Alpha synuclein is highly expressed in the brain, the second most lipid-rich organ, and exhibits binding  
78 properties with lipid membranes, thereby altering their structure and resulting in the formation of  
79 toxic alpha-synuclein oligomers<sup>7,8</sup>. There is much interest on how lipid aberrations could contribute  
80 to PD, as several risk genes exert known lipid-related functions<sup>9</sup>. An increase in serum lipids such as  
81 low-density lipoprotein (LDL) and its metabolites are correlated with oxidative stress in the brain  
82 through the generation of Lewy bodies, though there are conflicting studies suggesting that  
83 cholesterol and triglyceride levels are neuroprotective<sup>10-13</sup>. The role of lipid-lowering agents, such as  
84 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) inhibitors, Niemann-Pick C1-like 1 (NPC1L1)  
85 inhibitor, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, may be of therapeutic  
86 interest to ameliorate PD risk by targeting brain cholesterol metabolism and associated pathways but

87 further studies are required to clarify these outcomes due to the bidirectional effect of lipids in PD<sup>14</sup>.

88 In this study, we leveraged genetic variants proxying LDL lowering agents through HMGCR, NPC1L1,  
89 and PCSK9 inhibitors to determine its association with PD. Genetic proxies have been successfully  
90 used to study the effect of lipid-lowering drugs which target alleles encoding various molecular stages  
91 in VLDL trafficking and cholesterol metabolism<sup>15</sup>. To establish casual associations of modifiable  
92 exposures such as genetic proxies for lipid-lowering therapies in PD, we utilized a two-sample  
93 Mendelian randomization (MR) framework to reduce reverse causation biases and less likely to be  
94 influenced by confounding factors<sup>15</sup>. This study aimed to investigate the relationship between lipid-  
95 lowering medication and PD.

96

## 97 **Methods**

### 98 **Study Design**

99 MR is a statistical technique that utilizes genetic variants as instrumental variables (IVs) to establish  
100 causal inferences between exposures and outcomes. This study employed the two sample MR  
101 framework to investigate the effects of genetic variation in lipid-lowering drug targets on the risk of  
102 Parkinson's disease (PD)<sup>16</sup>. Exposure and outcome data were extracted from public genome wide  
103 association study (GWAS) summary datasets conducted on two independent, non-overlapping  
104 populations. risk of Parkinson's disease. The details of the framework are presented in **eFigure 1**.

### 105 **LDL GWAS Data**

106 Due to the unavailability of GWAS data on the exposure (protein targets of lipid-lowering drugs) and  
107 considering reducing LDL levels is a confirmed physiological response to lipid-lowering drug treatment,  
108 our study opts to use the available LDL as a biomarker of interest. This choice enables us to infer the  
109 effects of genetic variations in lipid-lowering drugs on the. Genetic associations with LDL were  
110 extracted from the largest GWAS dataset conducted by the Global Lipids Genetics Consortium,  
111 involving 1.3 million individuals of European ancestry. The details of primary study is provided in  
112 reference<sup>17</sup>.

### 113 **Parkinson's Disease GWAS Data**

114 The summary statistics for PD were extracted from the two GWAS datasets, which were published by  
115 the International Parkinson's Disease Genomics Consortium. The first GWAS dataset consisted of  
116 1,843 cases and 216,630 controls<sup>6</sup>. The other GWAS dataset focused on the motor subtype of PD  
117 consisted of 1,570 cases and 1,259 controls, where the tremor-dominant (TD) was defined as 1 and  
118 considered the case group, and the postural instability/gait difficulty (PIGD) was defined as 0 and  
119 served as the control group<sup>18</sup>. Both GWAS dataset were conducted on individuals of European  
120 ancestry to minimize potential bias from population stratification.

### 121 **Instrument Selection**

122 The IVs in this study were screened for the genes that encode lipid-lowering drug target proteins.  
123 Variations within and around these genes were used to assess the effect of drug use on exposure  
124 factors and outcomes. Three major classes of lipid-lowering drugs were identified, including 3-  
125 hydroxy-3-methylglutaryl-CoA reductase (HMGCR) inhibitors, Niemann-Pick C1-like 1 (NPC1L1)

126 inhibitors, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Detailed information  
127 about the protein targets and encoding genes for these drugs is provided in **Table 1**.

128 The single-nucleotide variations (SNVs) were designated within each encoding gene (within  $\pm 100$ kb  
129 base pairs of the gene location). Following this, variants with p-values greater than  $5 \times 10^{-8}$  and a  
130 minor allele frequency (MAF) below 0.01 were excluded in the GWAS data for LDL. The remained  
131 variants for each lipid-lowering drug target were selected as IVs and clumped with an  $R^2$  of 0.1, a  
132 window size of 10000 kb, and the reference population set to EUR. The detailed screening process of  
133 IVs for lipid-lowering drug is shown in **Figure 1**.

#### 134 **Positive Control Analyses**

135 In order to substantiate IVs selection, positive control analyses were performed using hyperlipidemia  
136 and coronary artery disease (CAD) as outcomes. Furthermore, three obesity-related traits were used  
137 as additional outcomes for validation, including body mass index (BMI), waist circumference (WC),  
138 and hip circumference (HC).

#### 139 **Statistical Analysis**

140 The present investigation integrated the IV-exposure association derived from the LDL GWAS data  
141 with the IV-outcome association obtained from the Parkinson's disease GWAS data to create  
142 harmonized data for the MR study. To safeguard the validity of the IV, it is crucial to adhere to three  
143 fundamental assumptions. The initial assumption, known as relevance, necessitates that the genetic  
144 variants are significantly associated with the exposure. Evaluation of the strength of the IV was  
145 conducted through the computation of F statistics, derived as the square of the beta divided by the

146 square of the standard error, with F statistics exceeding 10 indicative of robust IV strength. The  
147 second assumption, independence, posits that the genetic variants remain unaffected by potential  
148 confounding factors, a condition typically fulfilled owing to the random assortment of genetic variants  
149 during conception. The third assumption, exclusion restriction, asserts that the variants exclusively  
150 influence the outcome through the designated exposure, thereby precluding horizontal pleiotropy.  
151 Evaluation of horizontal pleiotropy was conducted utilizing the MR Egger method, and non-significant  
152 results suggest the absence of horizontal pleiotropy. In instances where all three assumptions are met,  
153 the Inverse Variance Weighted (IVW) method is applied to yield unbiased causal estimates pertaining  
154 to the associations between exposures and outcomes.

155 The F-statistic was calculated by dividing the square of beta by the square of the standard error, where  
156 an F-statistic value greater than 10 indicating sufficient instrument strength. The Cochran Q test was  
157 employed to assess heterogeneity within IVs, and non-significant results signify the absence of  
158 heterogeneity. To mimic the LDL-lowering effects of lipid-lowering drugs, the MR estimates were  
159 standardized to a 1 mmol/L decrease in LDL. Following Bonferroni corrected principle, the significance  
160 level of multiple testing for 3 drugs classes was set as  $p$  value  $< 0.017$  ( $0.05/3$ ).

161 For the lipid-lowering drugs identified to be associated with Parkinson's disease, Bayesian  
162 colocalization analysis was conducted specifically within the target gene region for LDL and  
163 Parkinson's disease. Another sensitivity analysis was the leave-one-out method, which entails  
164 systematically excluding each variant within the drug's target gene region and subsequently  
165 calculating the meta-effects of the remaining variants. The absence of statistically significant changes  
166 in MR estimates following the removal of each variant implies the robustness of the obtained results.



167 All analyses were performed in R (version = 4.3.1), mainly utilizing the TwoSampleMR (version = 0.5.7)  
168 and coloc (version = 5.2.3) packages. This study follows the Strengthening the Reporting of  
169 Observational Studies in Epidemiology (STROBE) MR guidelines.

## 170 **Data Availability**

171 All GWAS data analyzed in this study are publicly available. The LDL GWAS data is downloaded from  
172 the website of the Global Lipids Genetics Consortium ([https://csg.sph.umich.edu/willer/public/glgc-](https://csg.sph.umich.edu/willer/public/glgc-lipids2021)  
173 [lipids2021](https://csg.sph.umich.edu/willer/public/glgc-lipids2021)). The PD GWAS data is released in the resources page of International Parkinson's Disease  
174 Genomics Consortium (<https://www.pdgenetics.org/resources>). The GWAS data for positive control  
175 analyses are available through the IEU Open-GWAS Project database (<https://gwas.mrcieu.ac.uk/>).  
176 The corresponding GWAS-ids are ebi-a-GCST90104006 for hyperlipidemia; ebi-a-GCST003116 for  
177 coronary artery disease; ieu-b-40 for BMI; ukb-b-9405 for WC and ukb-b-15590 for HC. All code for  
178 MR analyses is available in a GitHub repository.

179

## 180 **Results**

### 181 **Instrument Selection**

182 For the primary analysis, 22 variants were selected to proxy LDL lowering through inhibition of  
183 HMGCR (mean F-statistic of 194), 12 for NPC1L1 (mean F-statistic of 109), and 37 for PCSK9 (mean F-  
184 statistic of 286). Detailed data of the IVs to proxy lipid-lowering drugs are shown in **eTable 1**.

### 185 **Positive Control Analyses**

186 As shown in **Figure 2**, genetic variations in *HMGCR*, *NPC1L1*, and *PCSK9* were significantly associated  
187 with a reduced risk of hyperlipidemia and CAD (**Figure 2, panels A and B**). For obesity-related traits  
188 (**Figure 2, panels C-E**), genetic variation in *HMGCR* was significantly correlated with increased BMI,  
189 WC, and HC. However, genetic variations in *NPC1L1* and *PCSK9* demonstrated no apparent correlation  
190 with BMI, WC, and HC. Positive control analysis data for each lipid-lowering drug class are available  
191 in **eTable 2-6**.

### 192 **Effects of Genetic Variation in lipid-lowering drug Targets on PD risk**

193 We conducted MR analysis using two PD GWAS datasets, and the results are illustrated in **Figure 3**.  
194 For the unstratified PD dataset, the MR analysis results revealed a significant association between  
195 genetic variation in *HMGCR* and a reduced risk of PD at the Bonferroni-corrected threshold (odds ratio  
196 [OR] = 0.54, 95% CI 0.34-0.86,  $p = 0.009$ , **Figure 3A**). However, there was no apparent correlation  
197 between genetic variations in *NPC1L1* and *PCSK9* and the risk of PD.

198 Interestingly, further MR analysis on the PD dataset stratified by motor function showed that,  
199 compared to the PIGD subtype, genetic variation in *HMGCR* was significantly associated with an  
200 increased risk of the TD subtype at the Bonferroni-corrected threshold (OR = 8.43, 95% CI 2.12-33.52,  
201  $p = 0.0025$ , **Figure 3B**). Additionally, genetic variation in *NPC1L1* showed a trend toward increased risk  
202 for the TD subtype (OR = 13.09, 95% CI 1.03-166.64,  $p = 0.0475$ ), while genetic variation in *PCSK9*  
203 exhibited a trend toward decreased risk for the TD subtype (OR = 0.28, 95% CI 0.08-0.94,  $p = 0.0398$ ).  
204 Unfortunately, the  $p$ -values for MR analysis of these two gene variations exceeded the Bonferroni-  
205 corrected threshold ( $p < 0.017$ ).

206 As evidence suggested that cognitive function declines more rapidly, and prognosis is worse in PIGD  
207 patients compared to TD patients. Our analysis suggests that the use of HMGCR and NPC1L1 inhibitors  
208 may contribute to the transition of PD patients from PIGD subtype to TD subtype, while the use of  
209 PCSK9 inhibitors may pose a risk of worsening PD. No heterogeneity or pleiotropy was detected within  
210 the IVs in both PD GWAS datasets (**Figure 3**,  $p$ -values for heterogeneity  $> 0.05$ ,  $p$ -values for pleiotropy  $>$   
211  $0.05$ ). Detailed MR analysis data are presented in **eTable 7-9**.

### 212 **Sensitivity Analysis**

213 Colocalization analysis was conducted for LDL and PD within *HMGCR* (**eTable 10**), as well as co-  
214 localization analysis for LDL and PD motor subtype within both *HMGCR* and *PCSK9* (**eTable 11**). The  
215 results of the colocalization analysis indicated a low probability of shared random variation between  
216 LDL and PD within *HMGCR* (0.87%), and similarly low probabilities within both *HMGCR* and *PCSK9* for  
217 the motor subtype of PD (5.31% and 8.22%, respectively).

218 The findings suggest that there is no high probability of shared causal variants for LDL and PD  
219 (including the PD motor subtype) within the coding regions of *HMGCR* and *PCSK9*. However, in the  
220 regional plot illustrating the associations of LDL and PD within  $\pm 100$ kb of *HMGCR*, rs12916 emerged  
221 as the leading SNP associated with LDL, while rs10942735 was identified as the leading SNP associated  
222 with PD within the same genomic region. Notably, these two leading SNPs were in close proximity,  
223 that revealed a trend of colocalization between LDL and PD (**eFigure 2**).

224 Additionally, in the PD GWAS datasets, leave-one-out sensitivity analyses were conducted for the  
225 genetic variations in *HMGCR* and *PCSK9*. The analyses demonstrated the robustness of the results,

226 indicating that after excluding each SNP, the overall error lines show minimal changes (all error lines  
227 are either to the right or left of 0), as shown in **eFigure 5-7**.

228

## 229 **Discussion**

230 This study investigated the effects of genetic variations in lipid-lowering drugs on the PD risk using a  
231 combination of LDL genetic dataset in ~1,300,000 participants and two PD genetic datasets,  
232 consistent of 1,843 PD cases and 216,630 control in the first dataset and 1,570 PD cases and 1,259  
233 controls in the second dataset. To the best of our knowledge, this is one of the largest studies with  
234 strong validation suggesting a causal association between HMGCR inhibition and a reduced risk of PD.  
235 Besides, this study was the first MR to investigate the association between genetic variation in lipid-  
236 lowering drug and the subtypes of PD.

237 A handful of literature has explored the association between lipid-lowering drugs or serum lipid levels  
238 and PD, yet the results have been inconsistent<sup>19-26</sup>. In a MR study using a Danish dataset, no  
239 association was detected between LDL and the risk of PD, whereas a separate MR study conducted  
240 by a Swedish team suggested a causal inverse association of LDL with PD risk<sup>19,27</sup>. Another recent MR  
241 study did not project an elevated risk of PD with statin exposure<sup>20</sup>. However, the results lacked  
242 sufficient precision to conclusively support preventive benefits. Nevertheless, this does not negate  
243 the potential advantages of on-target effects associated with statin use for PD prevention through  
244 alternative mechanisms<sup>20</sup>. However, all of these MR studies have their own statistical limitations.  
245 Other non-MR studies have also reported varied conclusions<sup>21-25</sup>. Interpreting the above studies

246 alongside our study results, which showed that only HMGCR inhibition, not NPC1L inhibition and  
247 PCSK9 inhibition, was correlated with a reduced risk of PD. The result provided evidence that HMGCR  
248 inhibitors may modify the pathogenesis of PD through a mechanism different from lowering LDL.  
249 Indeed, multiple studies have proposed the protective effects of HMGCR inhibitors on  $\alpha$ -synuclein  
250 aggregation through mechanisms such as antioxidation and promotion of neural repair<sup>28-30</sup>. Other  
251 suggested mechanisms involve HMGCR inhibitors preventing neuronal injury by mitigating microglia  
252 and autophagy activation<sup>31-33</sup>. As HMGCR inhibitors can cause a dose-dependent reduction in  
253 coenzyme Q10, the protective effects of HMGCR inhibitors may be compromised by mitochondrial  
254 dysfunction if the dose surpasses a specific threshold<sup>34</sup>. Nonetheless, this potential explanation for  
255 the inconsistency in previous studies warrants further investigation.

256 Another discovery from this study implied that incorporating HMGCR inhibitors may facilitate the shift  
257 of PD patients from the less favorable PIGD subtype to the more favorable TD subtype. The  
258 mechanisms behind the observations in the current study were not fully understood and necessitate  
259 additional research. However, previous studies have pointed to the involvement of various neural  
260 pathways in contributing to the PIGD phenotype of Parkinson's disease<sup>35-37</sup>. For example, some  
261 literature hinted at a connection between the severity of PIGD and amyloid  $\beta$  pathology<sup>35,38</sup>. The  
262 neuroprotective impact of HMGCR inhibitors on amyloid  $\beta$ -induced neurotoxicity may offer a partial  
263 explanation for the effect observed on the PIGD subtype<sup>39</sup>. Other studies suggested that elevated  
264 GABA levels or reduced acetylcholine may play a role in the development of the PIGD phenotype in  
265 Parkinson's disease, and HMGCR inhibitors might be involved in modifying the pathogenesis<sup>40,41</sup>.  
266 Given functional network alterations within cerebro-cerebellar motor pathways were identified  
267 among PD motor subtypes, we contemplate whether HMGCR inhibitors contribute to the alterations,

268 warranting further exploration in future studies<sup>37</sup>.

269 This study possesses several strengths. First, it involves large sample sizes from public GWAS datasets  
270 for analysis. The inclusion of such substantial and robust data enables study replication and  
271 diminishes random errors. In addition, all the GWAS datasets used were conducted on individuals of  
272 European ancestry, thereby minimizing potential biases arising from population stratification.  
273 Secondly, the two-sample MR study design may overcome the challenges of confounding between  
274 the exposure and outcome when estimating the causal exposure-outcome association. It also offers  
275 an opportunity to enhance statistical power and avoid reverse causality. Third, by performing a series  
276 of positive control analyses and sensitivity analyses that considered different patterns of pleiotropy,  
277 this study enhanced the robustness of the results, thereby reinforcing the evidence supporting our  
278 findings.

279 The study has several limitations. First, MR study needed to fulfill the instrumental variable  
280 assumptions which cannot be empirically verified. Even though rigorous statistical methods were  
281 employed, it is important to note that the complete exclusion of pleiotropy and bias effects cannot  
282 be guaranteed. Second, the lipid-lowering drug effect predicted by MR cannot be directly juxtaposed  
283 with the pharmacological effect observed in real life practice. The exposure instrumented by genetic  
284 variants persists throughout lifetime, whereas pharmacological intervention influences only a specific  
285 period of life. Consequently, the results of this study should be interpreted as evaluating the long-  
286 term modulation effects of drug target proteins. Third, lipid-lowering drugs may modify PD through  
287 interactions with other protein targets not captured in this MR study or via different mechanisms.  
288 Fourthly, the dataset utilized in this study only comprised individuals of European ancestry, limiting

289 the generalizability of the results to other ethnic groups. However causal effects are expected to be  
290 consistent across settings unless the mediating mechanisms differ, although the extent of response  
291 may vary.

292

### 293 **Conclusion**

294 The two way Mendelian Randomization result identified the casual association between genetic  
295 variations in *HMGCR* and PD, which suggested that lipid-lowering drugs may play a role in lowering  
296 risks of PD. However, the risk of TD subtypes are higher compared to PIGD subtypes, suggesting the  
297 bidirectional effects of the lipid-lowering drugs.

298 **Ethical approval statement**

299 None.

300 **Availability of data and materials**

301 Data are publicly available and can be accessed with the GWASID.

302 **Conflicts of Interest**

303 None

304 **Acknowledgements**

305 None

306 **Funding**

307 This research received no specific grant from any funding agency in the public, commercial, or not-  
308 for-profit sectors.

309 **Guarantor Statement**

310 All authors approved the final version of the manuscript.

311 **Author contributions**

312 L S, YF, JD Z: conception of study, preparation of figures, study design, data contribution, statistical  
313 analysis, data interpretation, manuscript drafting, and critical revision of the manuscript.



314 Y L, HL C, H H: literature search, data interpretation, literature search, data collection, manuscript

315 drafting.

316 BMY C, G T: critical revision of the manuscript.

317 OHI C, JD Z: conception of study and literature search, study design, data collection, and critical

318 revision of manuscript, study supervision.

319 **References**

- 320 1. Marino BLB, de Souza LR, Sousa KPA, et al. Parkinson's Disease: A Review from Pathophysiology  
321 to Treatment. *Mini Rev Med Chem* 2020; **20**(9): 754-67.
- 322 2. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and  
323 years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017:  
324 a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**(10159): 1789-  
325 858.
- 326 3. Reeve A, Simcox E, Turnbull D. Ageing and Parkinson's disease: why is advancing age the biggest  
327 risk factor? *Ageing Res Rev* 2014; **14**(100): 19-30.
- 328 4. Marras C, Lang A. Parkinson's disease subtypes: lost in translation? *J Neurol Neurosurg Psychiatry*  
329 2013; **84**(4): 409-15.
- 330 5. Kara E, Kiely AP, Proukakis C, et al. A 6.4 Mb duplication of the alpha-synuclein locus causing  
331 frontotemporal dementia and Parkinsonism: phenotype-genotype correlations. *JAMA Neurol* 2014;  
332 **71**(9): 1162-71.
- 333 6. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and  
334 heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet*  
335 *Neurol* 2019; **18**(12): 1091-102.
- 336 7. Fanning S, Selkoe D, Dettmer U. Parkinson's disease: proteinopathy or lipidopathy? *NPJ*  
337 *Parkinsons Dis* 2020; **6**: 3.
- 338 8. Fanning S, Haque A, Imberdis T, et al. Lipidomic Analysis of alpha-Synuclein Neurotoxicity  
339 Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment. *Mol Cell* 2019; **73**(5): 1001-14  
340 e8.


- 341 9. Hu G, Antikainen R, Jousilahti P, Kivipelto M, Tuomilehto J. Total cholesterol and the risk of  
342 Parkinson disease. *Neurology* 2008; **70**(21): 1972-9.
- 343 10. Xicoy H, Klemann CJ, De Witte W, Martens MB, Martens GJ, Poelmans G. Shared genetic etiology  
344 between Parkinson's disease and blood levels of specific lipids. *NPJ Parkinsons Dis* 2021; **7**(1): 23.
- 345 11. Jin U, Park SJ, Park SM. Cholesterol Metabolism in the Brain and Its Association with Parkinson's  
346 Disease. *Exp Neurobiol* 2019; **28**(5): 554-67.
- 347 12. Galper J, Dean NJ, Pickford R, et al. Lipid pathway dysfunction is prevalent in patients with  
348 Parkinson's disease. *Brain* 2022; **145**(10): 3472-87.
- 349 13. Rozani V, Gurevich T, Giladi N, et al. Higher serum cholesterol and decreased Parkinson's disease  
350 risk: A statin-free cohort study. *Mov Disord* 2018; **33**(8): 1298-305.
- 351 14. Williams DM, Bandres-Ciga S, Heilbron K, et al. Evaluating Lipid-Lowering Drug Targets for  
352 Parkinson's Disease Prevention with Mendelian Randomization. *Ann Neurol* 2020; **88**(5): 1043-7.
- 353 15. Sanderson E, Glymour MM, Holmes MV, et al. Mendelian randomization. *Nat Rev Methods*  
354 *Primers* 2022; **2**.
- 355 16. Schmidt AF, Finan C, Gordillo-Maranon M, et al. Genetic drug target validation using Mendelian  
356 randomisation. *Nat Commun* 2020; **11**(1): 3255.
- 357 17. Graham SE, Clarke SL, Wu KH, et al. The power of genetic diversity in genome-wide association  
358 studies of lipids. *Nature* 2021; **600**(7890): 675-9.
- 359 18. Alfradique-Dunham I, Al-Ouran R, von Coelln R, et al. Genome-Wide Association Study Meta-  
360 Analysis for Parkinson Disease Motor Subtypes. *Neurol Genet* 2021; **7**(2): e557.
- 361 19. Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybjærg-Hansen AJb. Low LDL cholesterol, PCSK9  
362 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian

- 363 randomisation study. 2017; **357**.
- 364 20. Williams DM, Bandres-Ciga S, Heilbron K, et al. Evaluating lipid-lowering drug targets for  
365 Parkinson's disease prevention with mendelian randomization. 2020; **88**(5): 1043-7.
- 366 21. Rozani V, Gurevich T, Giladi N, et al. Higher serum cholesterol and decreased Parkinson's disease  
367 risk: a statin-free cohort study. 2018; **33**(8): 1298-305.
- 368 22. Lee HJ, Han K, Kim YW, Yang SN, Yoon SYJP, Disorders R. Association between lipid levels and the  
369 risk of Parkinson's disease in individuals with diabetes mellitus: A nationwide population-based  
370 cohort study. 2023; **117**: 105881.
- 371 23. Nguyen TTH, Fournier A, Courtois É, et al. Statin Use and Incidence of Parkinson's Disease in  
372 Women from the French E3N Cohort Study. 2023.
- 373 24. Yan J, Qiao L, Tian J, et al. Effect of statins on Parkinson's disease: A systematic review and meta-  
374 analysis. 2019; **98**(12).
- 375 25. Jeong SH, Lee HS, Chung SJ, et al. Effects of statins on dopamine loss and prognosis in Parkinson's  
376 disease. 2021; **144**(10): 3191-200.
- 377 26. Zhao Y, Gagliano Taliun SAJFiN. Lipid-lowering drug targets and Parkinson's disease: A sex-specific  
378 Mendelian randomization study. 2022; **13**: 940118.
- 379 27. Fang F, Zhan Y, Hammar N, et al. Lipids, Apolipoproteins, and the risk of Parkinson disease: a  
380 prospective cohort study and a Mendelian randomization analysis. 2019; **125**(6): 643-52.
- 381 28. Eriksson I, Nath S, Bornefall P, Giraldo AMV, Öllinger KJEjocb. Impact of high cholesterol in a  
382 Parkinson's disease model: Prevention of lysosomal leakage versus stimulation of  $\alpha$ -synuclein  
383 aggregation. 2017; **96**(2): 99-109.
- 384 29. Yan J, Sun J, Huang L, Fu Q, Du GJJonr. Simvastatin prevents neuroinflammation by inhibiting N-

- 385 methyl-D-aspartic acid receptor 1 in 6-hydroxydopamine-treated PC12 cells. 2014; **92**(5): 634-40.
- 386 30. Tan W, Xue-bin C, Tian Z, et al. Effects of simvastatin on the expression of inducible nitric oxide  
387 synthase and brain-derived neurotrophic factor in a lipopolysaccharide-induced rat model of  
388 Parkinson disease. 2016; **126**(3): 278-86.
- 389 31. Lu D, Shen L, Mai H, et al. HMG-CoA reductase inhibitors attenuate neuronal damage by  
390 suppressing oxygen glucose deprivation-induced activated microglial cells. 2019; **2019**.
- 391 32. Bagheri H, Ghasemi F, Barreto GE, Sathyapalan T, Jamialahmadi T, Sahebkar AJB. The effects of  
392 statins on microglial cells to protect against neurodegenerative disorders: A mechanistic review. 2020;  
393 **46**(3): 309-25.
- 394 33. Kang SY, Lee S-B, Kim HJ, Kim H-T, Yang HO, Jang WJNL. Autophagic modulation by rosuvastatin  
395 prevents rotenone-induced neurotoxicity in an in vitro model of Parkinson's disease. 2017; **642**: 20-6.
- 396 34. Apostolopoulou M, Corsini A, Roden MJEjoci. The role of mitochondria in statin-induced  
397 myopathy. 2015; **45**(7): 745-54.
- 398 35. Zuo L-J, Piao Y-S, Li L-X, et al. Phenotype of postural instability/gait difficulty in Parkinson disease:  
399 relevance to cognitive impairment and mechanism relating pathological proteins and  
400 neurotransmitters. 2017; **7**(1): 44872.
- 401 36. Wen P, Li M, Xiao H, et al. Low-frequency stimulation of the pedunclopontine nucleus affects  
402 gait and the neurotransmitter level in the ventrolateral thalamic nucleus in 6-OHDA Parkinsonian rats.  
403 2015; **600**: 62-8.
- 404 37. Basaia S, Agosta F, Francia A, et al. Cerebro-cerebellar motor networks in clinical subtypes of  
405 Parkinson's disease. 2022; **8**(1): 113.
- 406 38. Müller ML, Frey KA, Petrou M, et al.  $\beta$ -amyloid and postural instability and gait difficulty in

- 407 Parkinson's disease at risk for dementia. 2013; **28**(3): 296-301.
- 408 39. Li HH, Lin CL, Huang CN. Neuroprotective effects of statins against amyloid  $\beta$ -induced  
409 neurotoxicity. *Neural Regen Res* 2018; **13**(2): 198-206.
- 410 40. Welter M-L, Demaille A, Ewenczyk C, et al. PPNa-DBS for gait and balance disorders in Parkinson's  
411 disease: a double-blind, randomised study. 2015; **262**: 1515-25.
- 412 41. El-Dessouki AM, Galal MA, Awad AS, Zaki HFJMn. Neuroprotective effects of simvastatin and  
413 cilostazol in L-methionine-induced vascular dementia in rats. 2017; **54**: 5074-84.
- 414


**Figure 1 Instrument Selection for Lipid-lowering Drug Classes**




The black line represents the DNA strand. The raised black box indicates the target gene, and the box with dashed line encompasses the region of  $\pm 100$ kb base pairs around the target gene. Each inverted triangle represents a genetic variant. Disappearing of inverted triangles indicates the exclusion of variants. HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; MAF, minor allele frequency; NPC1L1, Niemann-Pick C1-like 1; PCSK9, proprotein convertase subtilisin/kexin type.

**Figure 2 Estimated Effects of Genetic Variation in Lipid-lowering Drug Targets on Lipid Metabolism-Related Traits (Panel A-B) and Obesity-Related Traits (Panel C-E)**


**A.** Genetic variation in lipid-lowering drug targets on hyperlipidemia




**B.** Genetic variation in lipid-lowering drug targets on CAD




**C.** Genetic variation in lipid-lowering drug targets on BMI



**D.** Genetic variation in lipid-lowering drug targets on WC



**E.** Genetic variation in lipid-lowering drug targets on HC




Proxy gene is the gene that encodes the drug target protein. The estimated beta coefficients on BMI, WC, and HC are expected to be in agreement with the evidence from clinical trials, that is, taking in HMGCR inhibitor (ie, lovastatin) contributes to weight gain, and taking NPC1L1 inhibitor (ie, ezetimibe) and PCSK9 inhibitor (ie, alirocumab) has no effect on weight. BMI, body mass index; CAD, co




ronary artery disease; HC, hip circumference; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; IVs, instrumental variables; NPC1L1, Niemann-Pick C1-like 1; OR, odds ratio; PCSK9, proprotein convertase subtilisin/kexin type; SNVs, single-nucleotide variations; WC, waist circumference.

### Figure 3 Estimated Effects of Genetic Variation in Lipid-lowering Drug Targets on Parkinson's disease

#### A. Genetic variation in lipid-lowering drug targets on all types of PKD



#### B. Genetic variation in lipid-lowering drug targets on TD vs PIGD



Proxy gene is the gene that encodes the drug target proteins.  $P < 0.01$  indicates statistical significance, and  $0.01 < p < 0.05$  indicates suggestive significance.  $P$  for heterogeneity  $< 0.05$  indicates possible heterogeneity, whereas  $p$  for intercept  $< 0.05$  indicates substantial bias from pleiotropy. HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; IVs, instrumental variables; MR, mendelian randomization; NPC1L1, Niemann-Pick C1-like 1; OR, odds ratio; PCSK9, proprotein convertase subtilisin/kexin type; PIGD, postural instability/gait difficulty; PKD, Parkinson's disease; SNVs, single-nucleotide variations; TD, tremor-dominant.

**Table 1 Detailed Information of Lipid-lowering Drug Classes, Targets, and Encoding Genes.**

Drug class	Representative drug	Drug target ( <i>Encoding gene</i> )	Function of target protein	Gene region
3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) inhibitors	Lovastatin	HMGCR ( <i>HMGCR</i> )	NADPH binding	Chr5:74 632154 - 746579 29
Niemann-Pick C1-like 1 (NPC1L1) inhibitors	Ezetimibe	NPC1L1 ( <i>NPC1L1</i> )	Rab GTPase binding	Chr7:44 552134 - 445809 14
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors	Alirocumab	PCSK9 ( <i>PCSK9</i> )	Very-low-density lipoprotein particle receptor binding	Chr1:55 505221 - 555305 25